Half-year report · HY
4543.TEDINET S100X3VY
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥534.9bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥1.04T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥508.7bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥101.0bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥87.7bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥101.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥154.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥85.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥76.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥117.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥76.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.89T | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.83T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.75T | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥457.3bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥459.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.44T | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.37T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.31T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.33T | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥1.44T | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.37T | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.31T | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥217.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥221.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥194.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥204.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥102.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥210.8bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥100.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥71.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥82.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥38.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥38.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥108.8bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥65.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥52.13 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥79.01 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥42.57 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥52.12 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥78.99 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥42.56 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 75.9% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.8% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 75.0% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2025-04-01 → 2025-09-30 | ¥163m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥1.8bn |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥107.1bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥15.6bn |
| Cardiac And Vascular Companyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥322.1bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥87.0bn |
| Medical Care Solutions Companyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥105.6bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥13.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥534.8bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥116.2bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥132m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥98.0bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥13.2bn |
| Cardiac And Vascular Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥306.3bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥76.9bn |
| Medical Care Solutions Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥104.3bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥508.6bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥102.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 630
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | InterimDuration | 810000000 | JPY |
| Interest and dividend income ope cf IFRS | Prior1InterimDuration | -1660000000 | JPY |
| Interest and dividend income ope cf IFRS | InterimDuration | -1864000000 | JPY |
| Interest expenses ope cf IFRS | Prior1InterimDuration | 1091000000 | JPY |
| Interest expenses ope cf IFRS | InterimDuration | 885000000 | JPY |
| Foreign exchange loss gain ope cf IFRS | Prior1InterimDuration | -907000000 | JPY |
| Foreign exchange loss gain ope cf IFRS | InterimDuration | -2888000000 | JPY |
| Loss gain on sale and retirement of fixed assets ope cf IFRS | Prior1InterimDuration | -1333000000 | JPY |
| Loss gain on sale and retirement of fixed assets ope cf IFRS | InterimDuration | 255000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1InterimDuration | 8526000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | InterimDuration | -8620000000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1InterimDuration | -12649000000 | JPY |
| Decrease increase in inventories ope cf IFRS | InterimDuration | -13573000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1InterimDuration | -628000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | InterimDuration | -2380000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1InterimDuration | 4401000000 | JPY |
| Other changes in working capital ope cf IFRS | InterimDuration | 1763000000 | JPY |
| Subtotal ope cf IFRS | Prior1InterimDuration | 126298000000 | JPY |
| Subtotal ope cf IFRS | InterimDuration | 123348000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1InterimDuration | 1569000000 | JPY |
| Interest and dividends received ope cf IFRS | InterimDuration | 1917000000 | JPY |
| Interest paid ope cf IFRS | Prior1InterimDuration | -892000000 | JPY |
| Interest paid ope cf IFRS | InterimDuration | -938000000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1InterimDuration | -26076000000 | JPY |
| Income taxes refund paid ope cf IFRS | InterimDuration | -22340000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1InterimDuration | 100898000000 | JPY |
| Net cash provided by used in operating activities IFRS | InterimDuration | 101987000000 | JPY |
| Payments into time deposits inv cf IFRS | Prior1InterimDuration | -211000000 | JPY |
| Payments into time deposits inv cf IFRS | InterimDuration | -127000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf IFRS | Prior1InterimDuration | 1399000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf IFRS | InterimDuration | 203000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1InterimDuration | -31697000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | InterimDuration | -35455000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | Prior1InterimDuration | 2412000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | InterimDuration | 97000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1InterimDuration | -6859000000 | JPY |
| Purchase of intangible assets inv cf IFRS | InterimDuration | -6476000000 | JPY |
| Proceeds from government grants inv cf IFRS | Prior1InterimDuration | － | JPY |
| Proceeds from government grants inv cf IFRS | InterimDuration | 68000000 | JPY |
| Purchase of marketable securities inv cf IFRS | Prior1InterimDuration | -3784000000 | JPY |
| Purchase of marketable securities inv cf IFRS | InterimDuration | -3065000000 | JPY |
| Payments for acquisition of subsidiaries affiliates and other businesses inv cf IFRS | Prior1InterimDuration | -98000000 | JPY |
| Payments for acquisition of subsidiaries affiliates and other businesses inv cf IFRS | InterimDuration | -26253000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1InterimDuration | -38840000000 | JPY |
| Net cash provided by used in investing activities IFRS | InterimDuration | -71008000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1InterimDuration | 29969000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | InterimDuration | － | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1InterimDuration | -160278000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | InterimDuration | -15000000000 | JPY |
| Proceeds from issuance of bonds fin cf IFRS | Prior1InterimDuration | 69826000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |